Releases Geral
Constellation Brands Reports Third Quarter Fiscal 2025 Financial Results
AGÊNCIA DE COMUNICAÇÃO Conteúdo de responsabilidade da empresa 10 de janeiro de 2025
Constellation Brands, Inc.
ROCHESTER, N.Y., Jan. 10, 2025 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, reported today its third quarter fiscal 2025 financial results. A conference call to discuss the financial results and outlook will be hosted by President and Chief Executive Officer, Bill Newlands, and Chief Financial Officer, Garth Hankinson, on Friday, January 10, 2025 at 10:30 a.m. ET. Visit ir.cbrands.com to locate information for joining the conference call, or a live, listen-only webcast of the conference call.
ABOUT CONSTELLATION BRANDS
Constellation Brands (NYSE: STZ) is a leading international producer and marketer of beer, wine, and spirits with operations in the U.S., Mexico, New Zealand, and Italy. Our mission is to build brands that people love because we believe elevating human connections is Worth Reaching For. Its worth our dedication, hard work, and calculated risks to anticipate market trends and deliver more for our consumers, shareholders, employees, and industry. This dedication is what has driven us to become one of the fastest-growing, large CPG companies in the U.S. at retail, and it drives our pursuit to deliver whats next.
Every day, people reach for our high-end, iconic imported beer brands such as those in the Corona brand family like the flagship Corona Extra, Modelo Especial and the flavorful lineup of Modelo Cheladas, Pacifico, and Victoria; our fine wine and craft spirits brands including The Prisoner Wine Company, Robert Mondavi Winery, Casa Noble Tequila, and High West Whiskey; and our premium wine brands such as Kim Crawford and Meiomi.
As an agriculture-based company, we have a long history of operating sustainably and responsibly. Our ESG strategy is embedded into our business and our work focuses on serving as good stewards of the environment, enhancing social equity within our industry and communities, and promoting responsible beverage alcohol consumption. These commitments ground our aspirations beyond driving the bottom line as we work to create a future that is truly Worth Reaching For.
To learn more, visit www.cbrands.com and follow us on X, Instagram, and LinkedIn.
MEDIA CONTACTS | INVESTOR RELATIONS CONTACTS |
Amy Martin 585-678-7141 / amy.martin@cbrands.com Carissa Guzski 315-525-7362 / carissa.guzski@cbrands.com |
Joseph Suarez 773-551-4397 / joseph.suarez@cbrands.com Snehal Shah 847-385-4940 / snehal.shah@cbrands.com David Paccapaniccia 585-282-7227 / david.paccapaniccia@cbrands.com |
A PDF containing our Third Quarter Fiscal 2025 results and full financial tables is available at: http://ml.globenewswire.com/Resource/Download/316b8b28-c6d8-4632-812d-539d3999530a
A OESP nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP e sao de inteira responsabilidade da GlobeNewswire
Leia também
-
Releases Geral AACSB and AArU Begin Groundbreaking Partnership to Advance Quality Education Across the Arab World
15 de janeiro de 2025DUBAI, United Arab Emirates, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Association of Arab Universities (AArU) and AACSB International (AACSB) have formalized a strategic par
Saiba Mais -
Releases Geral Prazo para cadastro no DJE termina no dia 30 de setembro
27 de junho de 2024(DINO - 27 jun, 2024) - O prazo para cadastro das pessoas jurídicas de direito privado no Domicílio Judicial Eletrônico (DJE) passou do dia 30 de maio para 30
Saiba Mais -
Releases Geral Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder
3 de março de 2025UZEDY is currently approved in the US as a subcutaneous long-acting injectable (LAI) for use every one or two months for the treatment of schizophrenia in adults1LAI treatme
Saiba Mais